• By Shanna Seesz
  • Posted March 5, 2021

Dr. Brigette Tippin Davis on Forging a Career Path in Science—Her Way

Brigette Tippin Davis, PhD, FACMG, joined Ambry Genetics in 2011 and currently serves as Chief Scientific Officer where she oversees new clinical product development pipelines and research collaborations. She met virtually to talk about her career in STEM (Science, Technology, Engineering and Mathematics), the barriers she faced as a woman in …


  • By Alice Lam
  • Posted January 11, 2021

Leveraging Innovation to Improve the Identification of Patients with Hereditary Cancer

At the National Society of Genetic Counselors (NSGC) 2020 Virtual Annual Conference, Ambry discussed +RNAinsight® and the CARE Program™. The following addresses some of the questions we received. In case you missed this webinar, you can view a recording below. +RNAinsight®: Paired RNA and DNA Genetic Testing for Hereditary Cancer Risk   RNA-Related …


  • By Shanna Seesz
  • Posted January 4, 2021

Ambry Genetics Named Among Best Companies for Women and Workplace Culture

Ambry Genetics has been chosen out of 60,000 companies to receive awards for both Best Company for Women and Best Company Culture by Comparably, a leading workplace culture and compensation data reporting platform. The top 50 best rankings reflect anonymous employee sentiment ratings based on compensation, team leadership, environment, outlook, …


  • By Aaron Elliott, PhD, Chief Executive Officer
  • Posted October 21, 2020

+RNAinsight®: Finding Answers for More Patients - A Year in Review

It’s hard to believe that it has already been a year since we officially launched +RNAinsight, the first paired DNA/RNA genetic test for hereditary cancer. As we reach this milestone, I wanted to share with you why we set out to launch this product and reflect on our progress in finding more answers for patients. Ambry Genetics was founded with …


  • By Jessica Profato
  • Posted August 25, 2020

Neurology Test Menu Update

Available for samples received on/after August 31, 2020 We have updated our neurology test menu to provide more streamlined, up-to-date, and clinically relevant testing options to healthcare providers and patients. Contact your regional Account Executive or Genomic Science Liaison for more information. New Tests Test Name Test Code Description Genes Test …


  • By Ambry Genetics
  • Posted August 4, 2020

Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Breast Cancer

Ambry Genetics and the Mayo Clinic recently collaborated on the publication of “The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer from a Clinical Genetic Testing Cohort” in JNCI: The Journal of the National Cancer Institute (April 2020). Interested in hearing about the study from one …


  • By Alice Lam
  • Posted July 22, 2020

Hereditary Cancer Testing Menu Update

NOW AVAILABLE FOR ORDERS ON/AFTER JULY 22ND We are refreshing our hereditary cancer test menu based on the latest medical management guidelines, clinical literature, and customer feedback to deliver the most up-to-date, clinically relevant testing options to healthcare providers and patients. Contact your regional Account Executive or Genomic …


  • By Mary Pritzlaff, MS, CGC
  • Posted June 15, 2020

Study Finds Key Predictors of Positive Genetic Test Results in Men with Prostate Cancer

Genetic testing can identify men with prostate cancer who have pathogenic variants in genes associated with hereditary cancer. Results of genetic testing may be useful to inform treatment and management, identify men who are at greater risk for aggressive prostate cancer, and provide information about increased risks for other cancers for both …


  • By Ambry Genetics
  • Posted May 1, 2020

Ambry Genetics Virtual Booth ACMG 2020

Thank you for stopping by! Below you will find information on our research that was accepted by ACMG, along with some new and exciting things happening at Ambry. We hope that you are staying safe and healthy. Research Posters: 1) Genetic Testing Utilization Management: Saving Time, Saving Money, And Maximizing Clinical Utility For Patients- …


  • By Tyler Landrith, PhD
  • Posted March 5, 2020

Study Published in Nature Partner Journal Precision Oncology Confirms Clinical Utility of Simultaneous RNA and DNA Genetic Testing

DNA-based multigene panel testing (MGPT) is a commonly used approach for the detection of patients with or at-risk for inherited cancers.  Despite years of advancement in genetic testing, patients may still receive uncertain results or receive a negative result despite having a personal or family history suggestive of hereditary cancer.  RNA …